EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Carvacrol potentiates immunity and sorafenib anti-cancer efficacy by targeting HIF-1α/STAT3/ FGL1 pathway: in silico and in vivo study

Eman H Yousef, Amal M El Gayar, Nada F Abo El-Magd

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-024-03530-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Eman H Yousef und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. Ehamdy@horus.edu.eg. Hauptthemen laut MEDLINE: Sorafenib, Hypoxia-Inducible Factor 1, alpha Subunit, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mansoura University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia and tumor cell immunological escape greatly hinder the hepatocellular carcinoma (HCC) treatment efficiency. This study is designed to investigate the capability of carvacrol (CVR) to enhance sorafenib (SOR) anti-cancer efficacy and modulate anti-HCC immunity. CVR target and biological activities were predicted using Swiss Target Prediction website and PASS web server. UALCAN and LinkedOmics databases were used to examine hypoxia-inducible factor 1-alpha (HIF-1α) expression and the relationship between studied genes and tumor clinical features. Kaplan–Meier plotter (KM plotter) and TISIDB databases were used to illustrate correlation of HIF-1α with HCC prognosis and immune infiltration. The binding affinities of CVR to p300, KAT2B, CREBBP, and Hsp90 were demonstrated by molecular docking. In vivo analysis was performed in male Sprague–Dawley rats. The STAT3, JAK2, and fibrinogen-like protein 1 (FGL1) expressions were assessed by qRT-PCR. FGL1 was determined by ELISA. CD8 + T cell number was counted by flow cytometry. HIF-1α was determined by immunohistochemistry. CVR showed an HIF-1α inhibitory potential, which is highly expressed in HCC tissues. Also, elevated HIF-1α expression has been found to be correlated with clinicopathological characteristics, poor survival in HCC patients, and tumor immune cell infiltration. CVR/SOR enhanced liver functions and decreased AFP level. CVR/SOR hindered HCC progression by downregulating STAT3, JAK2, and FGL1. CVR/SOR induced tumor immunity via increasing CD8 + T cells. CVR/SOR is a powerful combination for tumor repression and enhancing SOR efficiency in HCC by modulating FGL1. Moreover, CVR/SOR might exert the aforementioned effects through HIF-1α/STAT3/FGL1 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibHypoxia-Inducible Factor 1, alpha SubunitCarcinoma, HepatocellularLiver NeoplasmsCymenesAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAnimalsSTAT3 Transcription FactorMaleHumansRats, Sprague-DawleyMolecular Docking SimulationSignal TransductionRatsDrug SynergismCell Line, Tumor

Stichwörter der Autor:innen

Drug resistanceHepassocinHypoxiaLiver cancerTumor immunityTumor microenvironment

Substanzen

SorafenibSTAT3 Transcription FactorHypoxia-Inducible Factor 1, alpha SubunitcarvacrolCymenesAntineoplastic AgentsHIF1A protein, humanSTAT3 protein, humanStat3 protein, ratHif1a protein, rat

Autor:innen und Institutionen

  • Biochemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. Ehamdy@horus.edu.eg.
  • Department of Pharmacology and Biochemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, 34518, Egypt. Ehamdy@horus.edu.eg.
  • Biochemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.

Förderung

  • Mansoura University

Zitieren

APA

Yousef, E. H., El Gayar, A. M., & Abo El-Magd, N. F. (2025). Carvacrol potentiates immunity and sorafenib anti-cancer efficacy by targeting HIF-1α/STAT3/ FGL1 pathway: in silico and in vivo study. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03530-9

Vancouver

Yousef EH, El Gayar AM, Abo El-Magd NF. Carvacrol potentiates immunity and sorafenib anti-cancer efficacy by targeting HIF-1α/STAT3/ FGL1 pathway: in silico and in vivo study. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03530-9

BibTeX
@article{Yousef2025,
  author = {Yousef, Eman H and El Gayar, Amal M and Abo El-Magd, Nada F},
  title = {Carvacrol potentiates immunity and sorafenib anti-cancer efficacy by targeting HIF-1α/STAT3/ FGL1 pathway: in silico and in vivo study},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-024-03530-9}
}
Kostenlos starten →